Which of the following is a side effect of fluoxetine?
All of the following are atypical antipsychotic drugs except?
Which is the drug of choice for schizophrenia?
What is a known side effect of phenothiazines?
Which of the following is NOT a use of fluoxetine?
What is the drug of choice for substitution therapy in morphine dependence?
Depot preparations are available for which of the following drugs?
Lithium may produce which of the following conditions?
Which of the following is a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)?
Chronic use of anti-psychotic drugs can lead to which of the following side effects?
Explanation: **Explanation:** Fluoxetine is a prototype **Selective Serotonin Reuptake Inhibitor (SSRI)**. While SSRIs primarily increase synaptic serotonin levels, they can exert secondary effects on other neurotransmitter systems. **Why Urinary Retention is the Correct Answer:** Although SSRIs are generally known for lacking the heavy anticholinergic burden of Tricyclic Antidepressants (TCAs), **Fluoxetine** possesses mild **antimuscarinic (anticholinergic) activity**. This can lead to symptoms such as dry mouth and, notably, **urinary retention** due to the inhibition of detrusor muscle contraction. In the context of this specific question, it is the recognized side effect among the choices provided. **Analysis of Incorrect Options:** * **A. Weight Gain:** Most SSRIs, especially Fluoxetine, are associated with **weight loss** or are weight-neutral during initial therapy. Significant weight gain is more characteristic of TCAs or Mirtazapine. * **B. Sweating:** While diaphoresis can occur in Serotonin Syndrome, it is not a classic side effect of standard Fluoxetine therapy compared to the anticholinergic "drying" effects. * **D. Diarrhoea:** While SSRIs often cause GI upset (nausea/loose stools) due to 5-HT3 stimulation, the anticholinergic profile of Fluoxetine specifically leans toward decreased GI motility and urinary hesitancy. **High-Yield Clinical Pearls for NEET-PG:** * **Longest Half-life:** Fluoxetine has the longest half-life (2–3 days) among SSRIs; its active metabolite, **norfluoxetine**, lasts 7–10 days. * **Washout Period:** Due to its long half-life, a 5-week washout period is required before starting an MAO inhibitor to avoid **Serotonin Syndrome**. * **Drug of Choice:** Fluoxetine is the preferred SSRI for **Bulimia Nervosa** and Depression in children/adolescents. * **Common Side Effects:** Sexual dysfunction (most common long-term), Akathisia, and Insomnia.
Explanation: **Explanation:** The classification of antipsychotics is based on their mechanism of action and side-effect profile. Antipsychotics are divided into **Typical (First Generation)** and **Atypical (Second Generation)** drugs. **Why Loxapine is the correct answer:** Loxapine is a **Typical (First Generation) Antipsychotic** belonging to the dibenzoxazepine class. Like other typical antipsychotics (e.g., Haloperidol, Chlorpromazine), its primary mechanism is the potent blockade of **Postsynaptic D2 receptors** in the mesolimbic pathway. While it has some serotonin-blocking properties, it is traditionally categorized as a first-generation agent due to its high affinity for D2 receptors and its potential to cause Extrapyramidal Symptoms (EPS) at higher doses. **Why the other options are incorrect:** * **Clozapine (Option A):** The prototype atypical antipsychotic. It has a low affinity for D2 receptors and a high affinity for D4 and 5-HT2A receptors. It is the drug of choice for **treatment-resistant schizophrenia**. * **Risperidone (Option B):** A benzisoxazole derivative and a potent 5-HT2A and D2 antagonist. It is a common atypical agent but is notable for causing hyperprolactinemia. * **Olanzapine (Option C):** A thienobenzodiazepine derivative. It is an atypical antipsychotic known for causing significant **weight gain and metabolic syndrome**. **High-Yield Clinical Pearls for NEET-PG:** * **Atypical vs. Typical:** Atypicals are defined by a lower risk of EPS and higher 5-HT2A/D2 receptor blockade ratio. * **Clozapine Monitoring:** Requires mandatory WBC count monitoring due to the risk of **agranulocytosis** (most serious side effect). It also lowers the seizure threshold. * **Quetiapine:** The atypical antipsychotic with the lowest risk of EPS; often preferred in Parkinson’s disease patients with psychosis. * **Aripiprazole:** Known as a "D2 partial agonist" or dopamine system stabilizer.
Explanation: **Explanation:** The management of schizophrenia has evolved from typical antipsychotics to **Atypical Antipsychotics (Second-Generation Antipsychotics)**, which are now considered the first-line treatment (Drug of Choice) for most patients. **1. Why Olanzapine is Correct:** Olanzapine is a potent atypical antipsychotic that acts as an antagonist at $D_2$ and $5-HT_{2A}$ receptors. It is preferred because it effectively treats both **positive symptoms** (hallucinations, delusions) and **negative symptoms** (apathy, social withdrawal) of schizophrenia. Crucially, it has a significantly lower risk of **Extrapyramidal Side Effects (EPS)** compared to older drugs, making it better tolerated for long-term use. **2. Why the other options are incorrect:** * **Haloperidol (Option B):** A high-potency typical antipsychotic. While effective for acute psychosis, it is no longer the first-line choice due to a very high incidence of EPS (dystonia, parkinsonism, akathisia). * **Lithium (Option C):** This is the drug of choice for **Bipolar Affective Disorder (BPAD)** and acute mania, not schizophrenia. It is a mood stabilizer, not an antipsychotic. * **Chlorpromazine (Option D):** A low-potency typical antipsychotic. It was the first antipsychotic discovered but is rarely used as a first-line agent today due to side effects like severe sedation, orthostatic hypotension, and skin pigmentation. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine** is the "Gold Standard" for **Treatment-Resistant Schizophrenia**, but it is not first-line due to the risk of **agranulocytosis** (requires mandatory WBC monitoring). * **Side Effects of Olanzapine:** Significant weight gain, hyperglycemia, and dyslipidemia (Metabolic Syndrome). * **Hyperprolactinemia** is common with typical antipsychotics and Risperidone, but less common with Olanzapine and Aripiprazole.
Explanation: **Explanation:** Phenothiazines, particularly **Chlorpromazine**, are known for causing specific ocular toxicities when used in high doses over long periods. **Why Option D is correct:** Chlorpromazine has a high affinity for melanin-containing tissues. It undergoes photochemical reactions when exposed to light, leading to the deposition of fine, particulate, brownish-yellow granules in the **anterior lens capsule** and the **posterior corneal endothelium**. These deposits typically follow a "star-shaped" or "stellate" pattern on the lens. While these deposits are often asymptomatic, they are a classic high-yield side effect of typical antipsychotics. **Analysis of Incorrect Options:** * **A. Epithelial keratopathy:** This is more commonly associated with drugs like **Amiodarone** (vortex keratopathy/cornea verticillata) or Chloroquine, rather than phenothiazines. * **B. Cataract:** While severe lens pigmentation can theoretically interfere with vision, phenothiazines do not typically cause standard senile or metabolic cataracts. However, **Quetiapine** (an atypical antipsychotic) requires periodic slit-lamp exams in some protocols due to a theoretical risk of cataracts. * **C. Central chorioretinopathy:** This is not a feature of phenothiazines. However, **Thioridazine** (another phenothiazine) is famous for causing **Retinitis Pigmentosa** (brownish discoloration of the retina) if the daily dose exceeds 800 mg. **NEET-PG High-Yield Pearls:** 1. **Chlorpromazine:** Think **C**orneal and **C**apsular (Lens) deposits. 2. **Thioridazine:** Think **T**oxic **R**etinopathy (Salt and pepper fundus). 3. **Mnemonic:** "Chlorpromazine for the Cornea, Thioridazine for the Retina." 4. Always monitor the "800 mg/day" ceiling dose for Thioridazine to prevent irreversible blindness.
Explanation: Fluoxetine is a **Selective Serotonin Reuptake Inhibitor (SSRI)**. The core pharmacological concept to remember for NEET-PG is that SSRIs increase synaptic serotonin, which leads to a **delay in ejaculation** as a common side effect. **Explanation of the Correct Answer:** * **Option A (Treatment of delayed ejaculation):** This is the correct answer because fluoxetine *causes* delayed ejaculation; it is never used to treat it. Using an SSRI in a patient who already has delayed ejaculation would worsen the condition. **Explanation of Incorrect Options:** * **Option B (Premature ejaculation):** Because SSRIs significantly prolong the ejaculatory latency time, they are used "off-label" to treat premature ejaculation. (Note: **Dapoxetine** is the specific SSRI approved for this due to its short half-life). * **Option C (Impulse control disorder):** SSRIs are first-line treatments for various impulse control disorders (like kleptomania or trichotillomania) and Obsessive-Compulsive Disorder (OCD) by modulating serotonergic pathways in the prefrontal cortex. * **Option D (Paraphilia):** In cases of hypersexuality or paraphilic disorders, fluoxetine is used to reduce libido and compulsive sexual urges. **NEET-PG High-Yield Pearls:** 1. **Half-life:** Fluoxetine has the longest half-life among SSRIs (due to its active metabolite **norfluoxetine**), requiring a 5-week washout period before starting an MAO inhibitor to avoid **Serotonin Syndrome**. 2. **Drug of Choice:** Fluoxetine is the preferred SSRI for **Bulimia Nervosa** and **Depression in children/adolescents**. 3. **Side Effects:** Common side effects include GI upset, insomnia, and sexual dysfunction (decreased libido and anorgasmia).
Explanation: **Explanation:** The management of opioid dependence (e.g., morphine or heroin) involves two phases: detoxification and maintenance (substitution) therapy. **Why Methadone is the Correct Answer:** **Methadone** is a long-acting synthetic µ-opioid agonist. In substitution therapy, it replaces the abused drug to prevent withdrawal symptoms and reduce "drug-seeking" behavior. Its efficacy lies in its **long half-life (24–36 hours)** and high oral bioavailability. This allows for once-daily dosing, providing a stable plasma concentration that avoids the rapid "high" (euphoria) and subsequent "crash" associated with short-acting opioids like morphine. **Analysis of Incorrect Options:** * **Clonidine:** An $\alpha_2$ agonist used to suppress the **autonomic symptoms** of opioid withdrawal (tachycardia, hypertension, sweating). It is not a substitute for the opioid itself and does not reduce craving. * **Naloxone:** A short-acting pure opioid antagonist. It is the drug of choice for **acute opioid poisoning** (overdose). If given to a dependent patient, it will precipitate immediate, severe withdrawal. * **Nalmefene:** A long-acting opioid antagonist (similar to Naltrexone). It is used for alcohol dependence or post-detoxification maintenance to prevent relapse, but never for substitution during active dependence. **High-Yield Clinical Pearls for NEET-PG:** * **Buprenorphine** (a partial µ-agonist) is another first-line agent for substitution therapy; it has a lower risk of overdose due to its "ceiling effect." * **Naltrexone** is used for **relapse prevention** only *after* the patient has been opioid-free for 7–10 days. * **Methadone side effect:** It can cause **QT interval prolongation**, requiring ECG monitoring.
Explanation: **Explanation:** Depot preparations are long-acting injectable (LAI) formulations designed to release the drug slowly over weeks, improving treatment adherence in chronic conditions like schizophrenia. **Why Risperidone is the correct answer:** Risperidone was the first atypical (second-generation) antipsychotic to be available as a depot preparation (e.g., Risperidone Consta). It is administered intramuscularly every 2 weeks. While Haloperidol and Olanzapine also have depot forms, in the context of standard NEET-PG questions and recent clinical focus, **Risperidone** is frequently highlighted as the prototype for atypical depot antipsychotics. **Analysis of Incorrect Options:** * **Haloperidol (Option A):** While Haloperidol Decanoate exists as a depot, it is a first-generation (typical) antipsychotic. In many MCQ formats, if both are present, the question often tests knowledge of newer atypical depots. However, technically, Haloperidol is also available as a depot. * **Olanzapine (Option C):** Olanzapine Pamoate is a depot formulation, but it is less commonly used due to the risk of **Post-injection Delirium Sedation Syndrome (PDSS)**, requiring mandatory 3-hour observation. * **Imipramine (Option D):** This is a Tricyclic Antidepressant (TCA). TCAs are administered orally; there are no depot preparations for antidepressants. **High-Yield Clinical Pearls for NEET-PG:** * **Common Depot Drugs:** Fluphenazine decanoate, Haloperidol decanoate, Risperidone, Paliperidone, and Aripiprazole. * **Indication:** Primarily used for patients with poor compliance or "revolving door" schizophrenia. * **Mechanism:** These are usually esterified in oil (typical) or microsphere-encapsulated (atypical) to slow absorption. * **Avoid:** Depot injections should never be given intravenously; they are strictly for deep intramuscular (IM) use.
Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Disorder, but it has a narrow therapeutic index and significant endocrine side effects. **1. Why Hypothyroidism is Correct:** Lithium is actively concentrated by the thyroid gland. It inhibits the synthesis and release of thyroid hormones ($T_3$ and $T_4$) by interfering with **iodine organification** and inhibiting **thyroglobulin colloid pinocytosis**. This leads to a compensatory rise in Thyroid Stimulating Hormone (TSH). Approximately 5–15% of patients on long-term Lithium therapy develop clinical or subclinical hypothyroidism. It is more common in females and those with pre-existing thyroid antibodies. **2. Analysis of Incorrect Options:** * **A. Hyperthyroidism:** While rare cases of Lithium-induced thyrotoxicosis have been reported (usually due to painless thyroiditis), the classic and most frequent association is hypothyroidism. * **C & D. Parathyroid Effects:** Interestingly, Lithium actually tends to cause **Hyperparathyroidism** (not hypo-). It increases the "set-point" of the calcium-sensing receptor in the parathyroid gland, leading to increased PTH secretion and subsequent **Hypercalcemia**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Check TSH levels every 6–12 months in patients on Lithium. * **Management:** Lithium-induced hypothyroidism is managed by adding **Levothyroxine**; Lithium does *not* necessarily need to be discontinued. * **Renal Side Effect:** Lithium most commonly causes **Nephrogenic Diabetes Insipidus** (resistance to ADH). * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels, leading to toxicity.
Explanation: ### Explanation **Correct Option: A. Duloxetine** Duloxetine is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)** [1]. It works by inhibiting the reuptake of both serotonin (5-HT) and norepinephrine (NE) in the synaptic cleft, thereby increasing their availability [1], [3]. * **Clinical Concept:** Unlike Selective Serotonin Reuptake Inhibitors (SSRIs), SNRIs have a dual mechanism [1]. Duloxetine is particularly unique because it is FDA-approved not just for depression and anxiety, but also for **chronic pain conditions** like diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain [2], as norepinephrine modulation helps inhibit descending pain pathways in the spinal cord. **Incorrect Options:** * **B. Sertraline & C. Citalopram:** Both belong to the **SSRI** class [1]. They selectively inhibit the reuptake of serotonin [3]. SSRIs are generally considered first-line treatment for depression due to a better side-effect profile compared to older antidepressants. * **D. Isoniazid:** This is an **anti-tubercular drug** (cell wall synthesis inhibitor). While it historically led to the discovery of MAO inhibitors (due to its structural similarity to Iproniazid), it is not used as an antidepressant. **High-Yield NEET-PG Pearls:** 1. **Other SNRIs:** Venlafaxine (can cause dose-dependent hypertension), Desvenlafaxine, and Milnacipran [1], [2]. 2. **Duloxetine & Stress Incontinence:** Duloxetine is also used in some countries for stress urinary incontinence (increases urethral sphincter tone). 3. **Side Effects:** SNRIs can cause increased blood pressure, heart rate, and insomnia due to the noradrenergic component. 4. **Contraindication:** Avoid SNRIs/SSRIs with MAO inhibitors to prevent **Serotonin Syndrome**.
Explanation: **Explanation:** Antipsychotic drugs, particularly Typical Antipsychotics (First Generation), act primarily by blocking Dopamine ($D_2$) receptors and various other neuroreceptors, leading to a wide spectrum of side effects. 1. **Tardive Dyskinesia (Option C):** This is the hallmark of **chronic (long-term)** antipsychotic use. It occurs due to the "up-regulation" or supersensitivity of dopamine receptors in the nigrostriatal pathway after prolonged blockade. It manifests as involuntary choreoathetoid movements, typically involving the tongue (fly-catching) and face. 2. **Parkinsonism (Option B):** This is a part of Extrapyramidal Symptoms (EPS). It occurs because $D_2$ blockade in the nigrostriatal pathway creates a functional deficiency of dopamine, mimicking Parkinson’s disease (tremors, rigidity, bradykinesia). While it can occur early, it often persists with chronic therapy. 3. **Orthostatic Hypotension (Option A):** Many antipsychotics (especially low-potency drugs like Chlorpromazine) block **$\alpha_1$-adrenergic receptors**. This prevents compensatory vasoconstriction when standing, leading to a drop in blood pressure. **Clinical Pearls for NEET-PG:** * **Tardive Dyskinesia:** Unlike other EPS, it may worsen if the antipsychotic dose is reduced or stopped. Treatment involves switching to **Clozapine** or using VMAT-2 inhibitors (e.g., Valbenazine). * **Hyperprolactinemia:** Chronic $D_2$ blockade in the tuberoinfundibular pathway leads to increased prolactin, causing galactorrhea and gynecomastia. * **Metabolic Syndrome:** More common with Atypical (Second Generation) antipsychotics like **Olanzapine** and **Clozapine**.
Antipsychotics: Typical and Atypical
Practice Questions
Antidepressants: SSRIs and SNRIs
Practice Questions
Tricyclic Antidepressants
Practice Questions
MAO Inhibitors
Practice Questions
Mood Stabilizers
Practice Questions
Anxiolytics
Practice Questions
Drugs for ADHD
Practice Questions
Drugs for Sleep Disorders
Practice Questions
Drugs for Dementia
Practice Questions
Drug-Induced Psychiatric Symptoms
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free